PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Avatrombopag→

Avatrombopag PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
570406-98-3
Molecular formula
C29H34Cl2N6O3S2
Molecular weight
649.7 g/mol
Drug class
Thrombopoietin receptor agonistoral platelet-production stimulator
Mechanism of action
Binds and activates the thrombopoietin receptor (c-Mpl) on haematopoietic stem cells and megakaryocyte progenitors, stimulating proliferation and differentiation and increasing platelet production.
Indications / reported uses
  • Treatment of thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure
  • Treatment of persistent or chronic immune thrombocytopenia (ITP) in adults with an insufficient response to previous treatment; use is product-specific and is not intended to normalise platelet counts

Sources: US DailyMed — DOPTELET (avatrombopag) · FDA prescribing information · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Avatrombopag PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Avatrombopag Permitted Daily Exposure (PDE) report (the Avatrombopag PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Avatrombopag Occupational Exposure Limit (OEL) report (the Avatrombopag OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.